Summary
Details
- Key highlights
- Algorithms and tables
- Indications for anticoagulation
- Indications: outcome event assessment
- Contraindications: absolute and relative contraindications
- Contraindications: bleeding risk assessment
- Initiating anticoagulation in primary care
- Initiating anticoagulation in acute inpatient care: initial therapy
- Initiating anticoagulation in acute inpatient care: transitioning to oral therapy
- Initiating anticoagulation in patients with HIT
- Warfarin initiation protocols
- Maintenance therapy: venous thromboembolism
- Maintenance therapy: atrial fibrillation
- Maintenance therapy: clinical re-evaluation
- Monitoring: general principles
- Monitoring: warfarin
- Monitoring: parenteral anticoagulants
- Monitoring: direct oral anticoagulants
- Surgery/procedure in anticoagulated patient: general principles
- Surgery/procedure in anticoagulated patient: management algorithm
- Special populations: pregnancy
- Special populations: breast-feeding
- Special populations: children
- Special populations: older patients
- Special populations: renal impairment
- Special populations: hepatic impairment
- Special populations: patients on antiplatelet therapy
- Complications: adverse effects
- Complications: bleeding
- Complications: management of bleeding
- Reversal agents: general principles
- Reversal agents: for heparins
- Reversal agents: for warfarin
- Reversal agents: for direct oral anticoagulants (DOACs)
- Anticoagulants: vitamin K antagonists
- Anticoagulants: oral direct thrombin inhibitors
- Anticoagulants: oral factor Xa inhibitors
- Anticoagulants: unfractionated heparin (UFH)
- Anticoagulants: low molecular weight heparins (LMWHs)
- Anticoagulants: parenteral factor Xa inhibitors
- Anticoagulants: heparinoids
- Anticoagulants: hirudins
- Anticoagulants: argatroban
- Patient information
- Guidelines
Contributors
Authors
Scott M. Stevens, MD
Thrombosis Clinic
Intermountain Medical Center
Murray
UT
Professor of Medicine
Department of Medicine
Intermountain Healthcare and University of Utah
Salt Lake City
UT
Disclosures
SMS declares that he has no competing interests.
Scott C. Woller, MD
Thrombosis Clinic
Intermountain Medical Center
Murray
UT
Professor of Medicine
Department of Medicine
Intermountain Healthcare and University of Utah
Salt Lake City
UT
Disclosures
SCW declares funding of an investigator initiated grant from Janssen Pharmaceuticals to Intermountain Health with no direct compensation to himself for research in the sum of $500,000.
Gabriel V. Fontaine, PharmD, MBA, BCCCP, BCPS
Clinical Pharmacy Manager
Critical Care and Emergency Medicine
Advanced Clinical Pharmacist
Neuroscience Critical Care
Intermountain Medical Center
Murray
UT
Associate Professor
Intermountain Healthcare and University of Utah
Salt Lake City
UT
Disclosures
GVF has received consulting fees and honoraria from Alexion Pharmaceuticals, AstraZeneca, Chiesi, and Anticoagulation Forum.
Acknowledgements
Dr Scott M. Stevens, Dr Scott C. Woller, and Dr Gabriel V. Fontaine would like to gratefully acknowledge Erin Sage Chang, a previous contributor to this topic.
Disclosures
ESC declares that she has no competing interests.
Peer reviewers
Lori-Ann Linkins, MD, MSc(Clin Epi), FRCPC
Associate Professor
Department of Medicine
McMaster University
Thrombosis Consultant
Juravinski Hospital and Cancer Centre
Hamilton
Ontario
Canada
Disclosures
LL has been reimbursed for educational lectures for Pfizer Canada (Fragmin; dalteparin) and has received lecture honoraria and research funding from Bayer, Inc (Xarelto; rivaroxaban).
Scott Kaatz, DO, MSc, FACP, SFHM
Senior Staff Hospitalist
Medical Director for Professional Development and Research
Division of Hospital Medicine
Henry Ford Hospital
Detroit
MI
Disclosures
SK has received speaker honorarium from Janssen, Boehringer-Ingelheim, Bristol Myer Squibb/Pfizer, CSL Behring, and Daiichi Sankyo; he has served as a consultant for Boehringer-Ingelheim, Bristol Myer Squibb/Pfizer, Janssen, Daiichi Sankyo, and Portola; he also is a board member (non-profit) of the Thrombosis and Hemostasis Societies of North America, the AC Forum, the National Certification Board of Anticoagulation Providers, and the National Blood Clot Alliance Medical and Scientific Advisory Board.
References
Key articles
Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018 Nov 27;2(22):3360-92.Full text Abstract
Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021 Dec;160(6):e545-608.Full text Abstract
Stevens SM, Woller SC, Baumann Kreuziger L, et al. Antithrombotic therapy for VTE disease: compendium and review of CHEST guidelines 2012-2021. Chest. 2024 Aug;166(2):388-404.Full text Abstract
Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e24S-43S.Full text Abstract
Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(suppl 2):e44S-88S.Full text Abstract
Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018 Nov 27;2(22):3257-91.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Calculators
Atrial Fibrillation CHA(2)DS(2)-VASc Score for Stroke Risk
Atrial fibrillation CHADS(2) score for stroke risk
More CalculatorsLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer